Comorbidities in lung cancer: Prevalence, severity and links with socioeconomic status and treatment

Postgraduate Medical Journal

Volumn 90, Issue 1064, 2014, Pages 305-310

  Grose, Derek ^a   Morrison, David S ^b   Devereux, Graham ^c   Jones, Richard ^a   Sharma, Dave ^d   Selby, Colin ^e   Docherty, Kirsty ^d   McIntosh, David ^a   Louden, Greig ^f   Nicolson, Marianne ^g   McMillan, Donald C ^b   Milroy, Robert ^h  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d INVERCLYDE ROYAL HOSPITAL   (United Kingdom)

^e QUEEN MARGARET HOSPITAL   (United Kingdom)

^f WISHAW GENERAL HOSPITAL   (United Kingdom)

^g ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^h GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; RESPIRATORY FUNCTION; SEVERITY OF ILLNESS INDEX; SOCIAL STATUS; TUMOR VOLUME; UNITED KINGDOM; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; NEEDS ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; SOCIAL CLASS; SURVIVAL; VERY ELDERLY; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NEEDS ASSESSMENT; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; SCOTLAND; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS; SURVIVAL ANALYSIS; WEIGHT LOSS;

EID: 84901342286     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2013-132186     Document Type: Article

References (36)

1. Gregor A, Thomson CS, Brewster DH, et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 2001;56:212-17.
2. Janssen-Heijnen MLG, Gatta G, Forman D, et al. Variation in survival of patients with lung cancer in Europe. Eur J Cancer 1998;34:2191-6.
3. Berrino F, De Angelis R, Milena Sant M, et al. and the EUROCARE working group: survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83.
4. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, Based on November 2008 SEER Data Submission, Posted to the SEER Web Site. Bethesda, MD: National Cancer Institute, 2009. http://seer.cancer.gov/csr/1975_2006/
5. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999;86:1867-76.
6. Laroche C, Wells F, Coulden R, et al. Improving surgical resection rate in lung cancer. Thorax 1998;53:445-9.
7. Cartman ML, Hatfield AC, Muers MF, et al. Lung cancer: district active retreatment rates affect survival. J Epidemiol Community Health 2002;56:424-9.
8. Damhuis RA, Schutte PR. Resection rates and postoperative mortality in 7,899 patients with lung cancer. EurRespir J 1996;9:7-10.
9. Birring SS, Peake MD. Symptoms and the early diagnosis of lung cancer. Thorax 2005;60:268-9.
10. Grose D, Devereux G, Brown L, et al. Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centres. J Thorac Oncol 2011;6:500-9.
11. Potosky AL, Saxman S, Wallace RB, et al. Population variations in the initial treatment of non-small cell lung cancer. J Clin Oncol 2004;22:3261-8.
12. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-46.
13. Extermann M. Measuring co-morbidity in older cancer patients. EurJCancer 2000;36:453-71.
14. Charlson ME, Pompei P. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
15. Tammemagi MC, Neslund-Dudas CMA, Simoff M, et al. Smoking and lung cancer survival: the role of co-morbidity and treatment. Chest 2004;125:27-37.
16. Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, et al. Effect of co-morbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004;59:602-7.
17. Colinet B, Jacot W, Bertrand D, et al. A new simplified co-morbidity score as a prognostic factor in non-small-cell lung cancer: description and comparison with the Charlson's index. Br J Cancer 2005;93:1098-105.
18. Birim O, Pieter Kappetein A, Bogers AJCC. Charlson co-morbidity index as a predictor of long term outcome after surgery for non-small-cell lung cancer. Eur J Cardiothorac Surg 2005;28:759-62.
19. Imperatori A, Harrison RN, Leitch DN, et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 2006;61: 232-9.
20. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada clinical trials group trials. J Clin Oncol 2008;26:54-9.
21. Erridge SC, Murray B, Williams L, et al. Improved survival from lung cancer in British Columbia compared to Scotland-are different treatment rates the whole story? Lung Cancer 2009;64:358-66.
22. Grose D, Devereux G, Milroy R. Co-morbidity in lung cancer. Important but neglected. A review of the current literature. Clinical Lung Cancer 2011;12:207-11.
23. West of Scotland Cancer Network. 2011 Audit report. http://www.woscan.scot.nhs. uk
24. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71.
25. Scottish Intercollegiate Guidelines Network (SIGN). Management of Patients with Lung Cancer. 2005. http://www.sign.ac.uk/pdf/sign80.pdf
26. Office of the Chief Statistician, Scottish Executive. Scottish Index of Multiple Deprivation 2006: Technical Report. http://www.scotland.gov.uk/Publications/2006/ 10/13142913/0
27. National Collaborating Centre for Clinical Conditions. Management of exacerbations of COPD. Thorax 2004;59:i131-56.
28. http://www.ccs.ca/download/position_statements/Grading%20of%20Angina.pdf
29. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th Ed. Boston, MA: Little, Brown & Co, 1994:253-6.
30. Lyden D, Lu M, Levine S, et al. Modified National Institutes of Health Stroke Scale for use in stroke clinical trials. Stroke 2001;32:1310.
31. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-14.
32. Rich A, Tata LJ, Stanley RA, et al. Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA). Lung Cancer 2011;72:16-22.
33. British Heart Foundation Statistics Database. 2009. http://www.heartstats.org
34. National Institute for Health and Care Excellence (NICE). Lung cancer (CG121): The diagnosis and treatment of lung cancer. 2011.
35. Wang S, Wong M, Hamilton N, et al. Impact of age and comorbidity on non-small cell lung cancer treatments in older Veterans. JCO 2012;30:1447-55.
36. Piccirillo J, Tierney R, Coastas I, et al. Prognostic importance of co-morbidity in a hospital-based cancer registry. JAMA 2004;291:2441-7.